Mutation Vif-22H, which allows HIV-1 to use the APOBEC3G hypermutation to develop resistance, could appear more quickly in certain non-B variants

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 4, 2011, Pages 941-942

  Yebra, G ^a   Holguin A ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

HIV drug resistance mutations; HIV 1 subtypes and recombinants; Mechanisms of resistance

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; ASPARAGINE; HISTIDINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; LYSINE; RNA DIRECTED DNA POLYMERASE; VIF PROTEIN;

ANTIVIRAL RESISTANCE; CONTROLLED STUDY; DNA POLYMORPHISM; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; LETTER; NONHUMAN; VIRUS GENE; VIRUS MUTATION;

ADAPTATION, BIOLOGICAL; CYTIDINE DEAMINASE; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV-1; HUMANS; MUTATION, MISSENSE; RECOMBINATION, GENETIC; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRULENCE FACTORS;

EID: 79952802313     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr012     Document Type: Letter

References (6)

1. Sheehy AM, Gaddis NC, Choi JD et al. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418: 646-50.
2. Harris RS, Bishop KN, Sheehy AM et al. DNA deamination mediates innate immunity to retroviral infection. Cell 2003; 113: 803-9.
3. Simon V, Zennou V, Murray D et al. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog 2005; 1: e6.
4. Jern P, Russell RA, Pathak VK et al. Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathog 2009; 5: e1000367.
5. Fourati S, Malet I, Binka M et al. Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals. AIDS 2010; 24: 2313-21.
6. Lisovsky I, Schader SM, Martinez-Cajas JL et al. HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes. Antimicrob Agents Chemother 2010; 54: 2878-85.